126 related articles for article (PubMed ID: 37819787)
1. Temporal change in aetiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients in New South Wales, Australia.
Yeoh YKJ; Dore GJ; Lockart I; Danta M; Flynn C; Blackmore C; Levy MT; George J; Alavi M; Hajarizadeh B
Intern Med J; 2024 Apr; 54(4):602-612. PubMed ID: 37819787
[TBL] [Abstract][Full Text] [Related]
2. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
3. Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ
J Hepatol; 2016 Dec; 65(6):1086-1093. PubMed ID: 27569777
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
Meringer H; Shibolet O; Deutsch L
World J Gastroenterol; 2019 Aug; 25(29):3929-3940. PubMed ID: 31413528
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
6. Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents.
Mathur K; Mazhar A; Patel M; Dakhoul L; Burney H; Liu H; Nephew L; Chalasani N; deLemos A; Gawrieh S
Clin Transl Gastroenterol; 2021 Nov; 12(11):e00420. PubMed ID: 34730559
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma (HCC) is changing its face: analysis of the temporal trends in aetiology and clinical patterns of HCC in South Australia.
Chandran V; Rajandran A; Loo KF; Bate J; Wigg A; Chinnaratha MA
Intern Med J; 2023 Jul; 53(7):1131-1136. PubMed ID: 36040722
[TBL] [Abstract][Full Text] [Related]
8. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma.
Mak LY; Cruz-Ramón V; Chinchilla-López P; Torres HA; LoConte NK; Rice JP; Foxhall LE; Sturgis EM; Merrill JK; Bailey HH; Méndez-Sánchez N; Yuen MF; Hwang JP
Am Soc Clin Oncol Educ Book; 2018 May; 38():262-279. PubMed ID: 30231359
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents.
Chen Q; Ayer T; Adee MG; Wang X; Kanwal F; Chhatwal J
JAMA Netw Open; 2020 Nov; 3(11):e2021173. PubMed ID: 33206188
[TBL] [Abstract][Full Text] [Related]
10. All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy.
Lockart I; Hajarizadeh B; Buckley N; Davison S; Prakoso E; Levy MT; George J; Dore GJ; Danta M
J Gastroenterol Hepatol; 2021 Dec; 36(12):3515-3523. PubMed ID: 34520088
[TBL] [Abstract][Full Text] [Related]
11. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
12. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL;
Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748
[TBL] [Abstract][Full Text] [Related]
13. Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study.
Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio H; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ
J Viral Hepat; 2018 May; 25(5):473-481. PubMed ID: 29194861
[TBL] [Abstract][Full Text] [Related]
14. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival.
Lockart I; Hajarizadeh B; Alavi M; Davison S; Prakoso E; Levy MT; George J; Dore GJ; Danta M
J Viral Hepat; 2021 May; 28(5):710-718. PubMed ID: 33481322
[TBL] [Abstract][Full Text] [Related]
16. Turning the Tide on Hepatitis C Virus-Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New Zealand.
Howell J; Majumdar A; Fink MA; Byrne M; McCaughan G; Strasser SI; Crawford M; Hodgkinson P; Stuart KA; Tallis C; Chen J; Wigg A; Jones R; Jaques B; Jeffrey G; Adams L; Wallace MC; Munn S; Gane E; Thompson AJ; Gow P
Liver Transpl; 2022 Feb; 28(2):236-246. PubMed ID: 34624175
[TBL] [Abstract][Full Text] [Related]
17. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
[TBL] [Abstract][Full Text] [Related]
18. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
19. Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme.
Hassan I; Gane E
Intern Med J; 2019 Nov; 49(11):1405-1411. PubMed ID: 30908822
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C care cascade before and during the direct-acting antiviral eras in New South Wales, Australia: A population-based linkage study.
Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ
J Viral Hepat; 2023 Mar; 30(3):250-261. PubMed ID: 36537024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
